论文部分内容阅读
目的:探讨胃肠道外间质瘤(EGIST)的临床特征、诊治及预后。方法:回顾性分析2012年1月至2015年7月川北医学院附属医院收治的21例EGIST患者的临床资料。结果:EGIST好发于肠系膜及网膜,分别占42.9%、33.3%;EGIST在肿瘤直径(≥10cm)、侵犯周围器官、危险度及恶性生物学行为均高于肠道GIST(P<0.05)。EGIST的R0切除率仅42.9%,合并脏器切除占61.9%,只有25%的患者术后进行分子靶向治疗,EGIST的1、2年总生存率为76.3%、42.4%,1、2年无进展生存率为68.0%、37.8%。结论:EGIST比肠道GIST有更高的不良生物学行为和更差的预后,合理的靶向治疗和手术时机是改善EGIST患者预后的有效手段。
Objective: To investigate the clinical features, diagnosis, treatment and prognosis of extraintestinal stromal tumors (EGIST). Methods: The clinical data of 21 patients with EGIST treated in the Affiliated Hospital of North Sichuan Medical College from January 2012 to July 2015 were retrospectively analyzed. Results: EGIST occurred in mesentery and omentum, accounting for 42.9% and 33.3% respectively. EGIST was higher in tumor diameter (≥10cm), invasive organs, risk and malignant biological behavior than GIST (P <0.05) . Only 42.9% of resected organ resections and 61.9% of resected organ combined with EGIST resulted in molecular targeted therapy in only 25% of patients. The overall 1 and 2 year survival rates of EGIST were 76.3%, 42.4% and 1 and 2 years respectively Progression-free survival rates were 68.0% and 37.8%. Conclusion: EGIST has higher adverse biological behavior and worse prognosis than intestinal GIST, and reasonable target therapy and operation timing are effective methods to improve the prognosis of patients with EGIST.